Swine Vaccines

Global Swine Vaccines Market to Reach US$2.1 Billion by 2030

The global market for Swine Vaccines estimated at US$1.7 Billion in the year 2024, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Inactivated, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Modified / Attenuated Live segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$462.6 Million While China is Forecast to Grow at 6.9% CAGR

The Swine Vaccines market in the U.S. is estimated at US$462.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$424.4 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Swine Vaccines Market – Key Trends & Drivers Summarized

Why Are Vaccines Becoming Central to Modern Swine Herd Management?

The global swine industry is confronting mounting challenges ranging from emerging infectious diseases and biosecurity threats to growing pressure for antibiotic reduction. In this context, vaccines have evolved from a preventive option to a foundational component of herd health strategies. With disease outbreaks like African Swine Fever (ASF), Porcine Reproductive and Respiratory Syndrome (PRRS), and Classical Swine Fever (CSF) causing devastating losses across major pork-producing regions, producers are increasingly leaning on vaccination protocols to mitigate risks and protect production continuity. Vaccines not only help control endemic diseases but also reduce the incidence of secondary infections, lowering the overall use of antimicrobials—a key goal in the global fight against antimicrobial resistance (AMR). Moreover, as pig farming scales up in intensity and density, the threat of rapid disease transmission grows, making routine immunization essential to minimize morbidity and mortality. As a result, vaccination is no longer seen as a cost but rather an investment in herd resilience, productivity, and long-term profitability, securing its place at the core of swine health management worldwide.

How Are New Vaccine Technologies Transforming Swine Disease Prevention?

Technological innovation is reshaping the development and delivery of swine vaccines, enabling faster, more effective, and more targeted immunization strategies. Advances in recombinant DNA technologies, viral vector platforms, and RNA-based vaccines are paving the way for next-generation solutions that offer broader protection with fewer side effects. Marker (DIVA) vaccines—those that differentiate infected from vaccinated animals—are gaining prominence, particularly for diseases with trade implications like CSF, as they support surveillance while maintaining disease-free certifications. Additionally, multivalent and combination vaccines are being developed to simplify vaccination schedules and reduce animal stress during administration. Intradermal and needle-free delivery systems are improving both animal welfare and biosecurity by minimizing tissue damage and cross-contamination risks. Diagnostic-linked vaccination (DLV) systems are also being piloted, integrating real-time disease diagnostics with vaccination decisions to improve timing and efficacy. These innovations are helping producers achieve higher immunity levels across herds, reduce labor time, and tailor vaccination programs to evolving disease pressures—marking a new era in data-driven, precision veterinary medicine.

What Role Do Regulations, Trade Dynamics, and Biosecurity Mandates Play?

The swine vaccines market is deeply influenced by regulatory frameworks, international trade conditions, and evolving biosecurity mandates. In many countries, vaccine use is closely regulated by government authorities such as the USDA, EMA, or CFDA, with strict approval pathways to ensure safety, efficacy, and compliance. As global pork trade continues to grow, especially between Asia, Europe, and the Americas, disease control becomes a prerequisite for export eligibility. Countries that can demonstrate effective vaccination programs and disease-free status have a significant advantage in maintaining market access and trade partnerships. This has pushed governments to fund mass vaccination campaigns, particularly for notifiable and transboundary diseases like ASF and Foot-and-Mouth Disease (FMD). Additionally, industry-driven certifications and retailer sourcing requirements are encouraging producers to maintain comprehensive vaccination records as part of animal welfare and sustainability commitments. Biosecurity has become a central tenet in swine farming, especially in light of recent outbreaks, and vaccines are now viewed as the first line of defense within integrated disease prevention protocols. The alignment of regulatory, trade, and farm-level expectations is reinforcing vaccine adoption as both a protective measure and a compliance requirement in modern swine production.

What’s Driving the Strong Growth in the Swine Vaccines Market?

The growth in the swine vaccines market is driven by a confluence of factors that span epidemiological trends, technological advancement, production system evolution, and global policy alignment. The rising prevalence of infectious and emerging diseases—such as PRRS, Mycoplasma hyopneumoniae, and ASF—is creating sustained demand for both prophylactic and emergency-use vaccines. Technological progress in adjuvant formulations, antigen discovery, and vaccine delivery is broadening product availability and effectiveness, opening up new segments for innovation. The global shift away from antibiotics—driven by regulatory bans, export standards, and consumer awareness—is amplifying the importance of vaccines as a primary disease control strategy. At the production level, intensification of swine farming and the consolidation of large-scale operations are increasing the economic value of herd health management, with vaccines playing a central role in risk mitigation. In parallel, public-private partnerships and government-funded immunization initiatives in Asia, Latin America, and Africa are supporting vaccine deployment in both commercial and smallholder systems. Improved cold chain logistics, the rise of veterinary health informatics, and the integration of vaccination into precision livestock farming platforms are further enhancing accessibility and impact. Together, these drivers are propelling the swine vaccines market forward—solidifying its position as a critical pillar of sustainable, scalable, and biosecure pork production worldwide.

SCOPE OF STUDY:

The report analyzes the Swine Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Inactivated, Modified / Attenuated Live, Others); Disease Type (Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo, Actinobacillus Pleuropneumonia, PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Others); Administration Route (Injectables, Intranasal, Oral)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Aptimmune Biologics
• Baseimmune
• Biogenesis Bago
• Boehringer Ingelheim International GmbH
• Cambridge Technologies
• Ceva Santé Animale
• Codagenix
• Elanco Animal Health Incorporated
• Genvax Technologies
• HIPRA
• Indian Immunologicals Limited
• iBio
• KM Biologics
• Merck & Co., Inc.
• Phibro Animal Health Corporation
• Ring Biotechnology Co Ltd.
• Sequent Scientific Limited
• Serum Institute of India
• Vaxxinova International BV
• Vetoquinol S.A.
• Virbac
• ViroVet

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.